Corcept Therapeutics Incorporated (0I3Q.L)
USD 72.63
(-2.15%)
USD 72.63
(-2.15%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 7.73 Million USD | -54.61% |
| 2022 | 17.03 Million USD | -5.12% |
| 2021 | 17.95 Million USD | -15.16% |
| 2020 | 21.15 Million USD | 21.56% |
| 2019 | 17.4 Million USD | 7.16% |
| 2018 | 16.24 Million USD | 93.91% |
| 2017 | 8.37 Million USD | 259.64% |
| 2016 | 2.32 Million USD | 38.47% |
| 2015 | 1.68 Million USD | 39.35% |
| 2014 | 1.2 Million USD | 10.13% |
| 2013 | 1.09 Million USD | 28.49% |
| 2012 | 853 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 7.19 Million USD | -6.99% |
| 2024 Q3 | 8.05 Million USD | -3.59% |
| 2024 Q2 | 8.35 Million USD | 16.13% |
| 2023 FY | 7.73 Million USD | -54.61% |
| 2023 Q3 | 7.51 Million USD | 8.65% |
| 2023 Q4 | 7.73 Million USD | 2.89% |
| 2023 Q1 | 16.56 Million USD | -2.74% |
| 2023 Q2 | 6.91 Million USD | -58.26% |
| 2022 Q4 | 17.03 Million USD | 181.69% |
| 2022 Q1 | 5.07 Million USD | -71.7% |
| 2022 FY | 17.03 Million USD | -5.12% |
| 2022 Q2 | 17.41 Million USD | 242.88% |
| 2022 Q3 | 6.04 Million USD | -65.28% |
| 2021 FY | 17.95 Million USD | -15.16% |
| 2021 Q2 | 4.66 Million USD | -5.64% |
| 2021 Q1 | 4.94 Million USD | -76.61% |
| 2021 Q4 | 17.95 Million USD | 259.43% |
| 2021 Q3 | 4.99 Million USD | 6.96% |
| 2020 Q3 | 4.81 Million USD | -2.23% |
| 2020 Q1 | 16.14 Million USD | -7.23% |
| 2020 Q2 | 4.92 Million USD | -69.49% |
| 2020 Q4 | 21.15 Million USD | 339.22% |
| 2020 FY | 21.15 Million USD | 21.56% |
| 2019 FY | 17.4 Million USD | 7.16% |
| 2019 Q2 | 17.86 Million USD | 257.36% |
| 2019 Q1 | 5 Million USD | -69.22% |
| 2019 Q3 | 5.46 Million USD | -69.43% |
| 2019 Q4 | 17.4 Million USD | 218.66% |
| 2018 Q1 | 7.78 Million USD | -7.04% |
| 2018 Q4 | 16.24 Million USD | 202.91% |
| 2018 Q3 | 5.36 Million USD | 8.39% |
| 2018 Q2 | 4.94 Million USD | -36.46% |
| 2018 FY | 16.24 Million USD | 93.91% |
| 2017 Q2 | 6.29 Million USD | -6.1% |
| 2017 FY | 8.37 Million USD | 259.64% |
| 2017 Q4 | 8.37 Million USD | 52.07% |
| 2017 Q3 | 5.5 Million USD | -12.56% |
| 2017 Q1 | 6.7 Million USD | 188.02% |
| 2016 Q3 | 2.32 Million USD | -43.16% |
| 2016 Q4 | 2.32 Million USD | 0.09% |
| 2016 Q1 | 1.91 Million USD | 13.67% |
| 2016 FY | 2.32 Million USD | 38.47% |
| 2016 Q2 | 4.09 Million USD | 114.12% |
| 2015 FY | 1.68 Million USD | 39.35% |
| 2015 Q3 | 1.6 Million USD | 10.54% |
| 2015 Q1 | 1.31 Million USD | 8.53% |
| 2015 Q4 | 1.68 Million USD | 4.86% |
| 2015 Q2 | 1.45 Million USD | 10.76% |
| 2014 Q2 | 1.07 Million USD | -4.88% |
| 2014 Q1 | 1.12 Million USD | 2.83% |
| 2014 FY | 1.2 Million USD | 10.13% |
| 2014 Q4 | 1.2 Million USD | 11.76% |
| 2014 Q3 | 1.08 Million USD | 0.75% |
| 2013 Q1 | 1.02 Million USD | 20.28% |
| 2013 FY | 1.09 Million USD | 28.49% |
| 2013 Q2 | 694 Thousand USD | -32.36% |
| 2013 Q3 | 1.02 Million USD | 47.69% |
| 2013 Q4 | 1.09 Million USD | 6.93% |
| 2012 FY | 853 Thousand USD | 0.0% |
| 2012 Q4 | 853 Thousand USD | -53.57% |
| 2012 Q3 | 1.83 Million USD | -24.62% |
| 2012 Q1 | 56 Thousand USD | 0.0% |
| 2012 Q2 | 2.43 Million USD | 4251.79% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | 35.712% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | 59.478% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | 87.051% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | 20.359% |
| bluebird bio, Inc. | 22.91 Million USD | 66.273% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -174.016% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 97.997% |
| Myriad Genetics, Inc. | 20.1 Million USD | 61.542% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 79.817% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 90.014% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.907% |
| Waters Corporation | 516.23 Million USD | 98.503% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.848% |
| Biogen Inc. | 2.52 Billion USD | 99.694% |
| Nektar Therapeutics | 16.1 Million USD | 51.991% |
| Perrigo Company plc | 1.14 Billion USD | 99.322% |
| Dynavax Technologies Corporation | 53.29 Million USD | 85.494% |
| Illumina, Inc. | 587 Million USD | 98.683% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | 25.472% |
| Heron Therapeutics, Inc. | 42.11 Million USD | 81.643% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 99.302% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | 29.714% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.7% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 88.221% |
| FibroGen, Inc. | 41.56 Million USD | 81.403% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 99.25% |
| OPKO Health, Inc. | 65.69 Million USD | 88.234% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 91.329% |
| Exelixis, Inc. | 17.32 Million USD | 55.377% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 99.699% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | 48.926% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 416.285% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 98.954% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 72.806% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 97.606% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 93.942% |
| Blueprint Medicines Corporation | 21.22 Million USD | 63.577% |
| Insmed Incorporated | 83.24 Million USD | 90.714% |
| TG Therapeutics, Inc. | 39.82 Million USD | 80.589% |
| Incyte Corporation | 62.97 Million USD | 87.725% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 97.65% |